[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-361363-105":59,"doc-detail-361363-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","clinical-impact-of-albumin-bilirubin-albi-score-in-patients-with-recurrent-esophageal-cancer-after-curative-treatment","Clinical Impact of Albumin-Bilirubin (ALBI) Score in Patients With Recurrent Esophageal Cancer After Curative Treatment","","The albumin-bilirubin (ALBI) score, used to evaluate pretreatment liver function, has been described as a prognostic marker across multiple malignancies. A retrospective review assessed its clinical impact in consecutive patients with recurrent esophageal cancer treated at Yokohama City University from 2005 to 2022. Overall survival (OS) after recurrence was the primary endpoint, with a secondary endpoint evaluating associations between ALBI and post-recurrence treatment course. ALBI-high patients had worse OS, and ALBI independently predicted OS.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinical-impact-of-albumin-bilirubin-albi-score-in-patients-with-recurrent-esophageal-cancer-after-curative-treatment/361363/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinical-impact-of-albumin-bilirubin-albi-score-in-patients-with-recurrent-esophageal-cancer-after-curative-treatment/361363.png","ImageObject",300,407,{"name":92,"@type":93},"hdkawk","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s primary endpoint for recurrent esophageal cancer?","Question",{"text":112,"@type":113},"The primary endpoint was overall survival (OS) after recurrence.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the ALBI score used in the analysis?",{"text":117,"@type":113},"Patients were stratified by an ALBI cut-off set at −2.80 into ALBI-low and ALBI-high groups, and ALBI was tested for its prognostic association with OS and treatment course after recurrence.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main findings regarding prognosis?",{"text":121,"@type":113},"ALBI-high patients showed significantly worse OS compared with ALBI-low patients, and multivariate analysis indicated the ALBI score was an independent prognostic factor for OS.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},361363,1790212090,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},3985747859855,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","doi: 10.21873/invivo.14454  \nClinical Impact of Albumin-Bilirubin (ALBI) Score in Patients With Recurrent Esophageal Cancer After Curative Treatment  \nTAIICHI KAWABE1,2*, TORU AOYAMA1,2*, ITARU HASHIMOTO1, YUKIO MAEZAWA1, SHO SATO1, TAKASHI KOSAKA1, MIKI KAYASHIMA1, MAKI TAKAGI1, KOHEI SEKIGUCHI1, KIYOKO SHIMADA1, NAOKO OKUDA1, MOMOKO FUKUDA1, MASAKI TAKAHASHI1, MIHWA JU1, NATSUMI KAMIYA1, YOSUKE ATSUMI1, KEISUKE KAZAMA1,  \nNOBUHIRO SUGANO1, AYAKOTAMAGAWA1, AYA SAITO2, TAKAKI YOSHIKAWA1 and NORIO YUKAWA1,2  \n1 Department of Gastrointestinal Surgery, Yokohama City University, Yokohama, Japan; 2 Department of Surgery, Yokohama City University, Yokohama, Japan  \nAbstract  \nBackground/Aim: The albumin-bilirubin (ALBI) score, which evaluates pretreatment liver function, has been reported as a prognostic factor in several malignancies. We conducted a retrospective study to clarify the prognostic impact of the ALBI score in patients with recurrent esophageal cancer.  \nPatients and Methods: We retrospectively reviewed the medical records and data of consecutive patients with recurrent esophageal cancer who received treatment, including best supportive care, at Yokohama City University from 2005 to 2022. The primary endpoint of the present study was overall survival (OS) after recurrence. The secondary endpoint was the association between the ALBI score and the treatment course after recurrence.  \nResults: Ninety patients were eligible for the present study. The median overall survival was 10.4 months (95% confidence interval=4.9-15.8 months). Based on previous studies and exploratory analyses of 1-and 3-year OS, the ALBI score cut-off was set at −2.80. The 90 patients were divided into the ALBI-low (ALBI score \u003C−2.80, n=29) and ALBI-high (ALBI score ≥−2.80, n=61) groups. The 1-and 3-year OS rates were 70.9% and 40.8% in the ALBI-low group and 35.5% and 13.7% in the ALBI-high group, respectively (p=0.007). In the multivariate analysis, the ALBI score was an independent prognostic factor for OS (hazard ratio=2.046, 95% confidence interval=1.164-3.594, p=0.013) . The first-line treatment rate tended to be higher in the ALBI-low group than in the ALBI-high group [89.7%(26/29) vs. 73.8%(45/61), p=0.084] .  \nConclusion: The ALBI score may be a promising prognostic factor for patients with recurrent esophageal cancer.  \nKeywords: ALBI, recurrence, esophageal cancer, survival.  \n*These Authors contributed equally to this study.  \nToru Aoyama, Department of Surgery, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Japan. Tel: +81 457872800, [e-mail:](e-mail: aoyamat@yokohama-cu.ac.jp)[ aoyamat@yokohama-cu.ac.jp](e-mail: aoyamat@yokohama-cu.ac.jp); Itaru Hashimoto, Department of Surgery, Yokohama City University, 3-9  \nuekcueuraive,dKaMnaazya1w1a, -k20u2, Y6o|kohamRevisae,JdaJpuanne. T1el4,: +28012465|78A7c2c800epte,edmailune:h2a8himot2026[o.ita.ic@yokohama-cu.ac.jp](o.ita.ic@yokohama-cu.ac.jp)  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n©2026 The Author(s) . Published by the International Institute of Anticancer Research.  \nIntroduction  \nEsophageal cancer is the seventh most common cancer and the sixth leading cause of cancer-related mortality worldwide (1). Chemoradiotherapy and/or chemotherapy are the standard treatments for patients with recurrent esophageal cancer (2-5). The prognosis of patients with recurrent esophageal cancer has gradually improved with the introduction of immune checkpoint inhibitors, advances in supportive care, and earlier diagnosis using modern imaging modalities (6-8) . However, the overall prognosis remains poor, with a median overall survival of less than 12 months. Therefore, the identification of reliable prognostic factors is essential to guide the development and selection of more effective treatment strategies for recurrent esophageal ","cbCaieANfVPsU7xj","https://ap.wps.com/l/cbCaieANfVPsU7xj","pdf",1135857,"English","# Background/Aim\n# Patients and Methods\n## Patients\n## Endpoints\n# Results\n## Survival and cut-off\n## Prognostic analysis\n# Conclusion","[{\"question\":\"What was the study’s primary endpoint for recurrent esophageal cancer?\",\"answer\":\"The primary endpoint was overall survival (OS) after recurrence.\"},{\"question\":\"How was the ALBI score used in the analysis?\",\"answer\":\"Patients were stratified by an ALBI cut-off set at −2.80 into ALBI-low and ALBI-high groups, and ALBI was tested for its prognostic association with OS and treatment course after recurrence.\"},{\"question\":\"What were the main findings regarding prognosis?\",\"answer\":\"ALBI-high patients showed significantly worse OS compared with ALBI-low patients, and multivariate analysis indicated the ALBI score was an independent prognostic factor for OS.\"}]","Clinical Impact of Albumin-Bilirubin (ALBI) Score in Patients With Recurrent Esophageal Cancer After Curative Treatment | PDF",1790144064,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f20d500ff4a6fe91773ed60cb1c14f47.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e93608c9d64fc49602e189ac3c5b056.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e40a0914a3de2f125ec47f852db296c8.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fc033dcd791acad8f55b5c57f455c4d2.webp",980,1306]